

Carasent - On Track Towards the Financial Targets

Redeye retains its positive view of Carasent following the Q3 report. We believe the strong CARR and further growth prospects – boosted by the new surgical module, for example – and a limited need for increased OPEX set Carasent for solid organic growth and expanding margins over the next few years.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Carasent - On Track Towards the Financial Targets